Accurate cell signatures for the advancement of personalized medicine
Sector: Hospital • Location: Switzerland
Source: EU Funding & Tenders Portal
Patient/individual specific cells, including induced pluripotent stem (iPS) cells will be crucial in defining tomorrow’s medicine owing to their uses in drug discovery, immunotherapy or cell therapy. These clinical applications require the utmost accurate and reliable identity and purity testing, however, the majority of cells stored worldwide fall short of a sufficient level of characterisation.
- Status
- Closed
- Sector
- Hospital
- Location
- Switzerland
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Accurate cell signatures for the advancement of personalized medicine
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Patient/individual specific cells, including induced pluripotent stem (iPS) cells will be crucial in defining tomorrow’s medicine owing to their uses in drug discovery, immunotherapy or cell therapy. These clinical applications require the utmost accurate and reliable identity and purity testing, however, the majority of cells stored worldwide fall short of a sufficient level of characterisation. This project aims at validatating and commercializing an innovative method of diagnostic and quality control for human cells. It is based on our unprecedented ability to measure the expression of millions of uncharted RNA biomarkers called TEs, genetic units that contribute over 50% of the genome but that have been completely disregarded until very recently, mainly due to the challenge imposed by their complex analysis. Our new methodology provides a high-density barcode of cellular identity, opening the door for individual-specific cells to broad applications in biotechnology and medicine alike. |
Location
Country | Switzerland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2026-01-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Switzerland
- SUN2CHEM
- BIOVERSYS (COVID-19) (IDFF)
- Helsinn New Cytotoxic Plant, Biasca
- Merck Biotech Development Facility, Corsier-sur-Vevey, Switzerland
- Thermo Fisher Scientific’s Biologics Manufacturing Facility, Lengnau, Switzerland
- AGORA Cancer Centre, Lausanne
- Personalised medical platform for patients with autoimmune diseases
- Acute care for addicts (ASBO)
